Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML

Acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITD) mutation is an aggressive hematologic malignancy associated with frequent relapse and poor overall survival. The tyrosine kinase inhibitor gilteritinib is approved for the treatment of relapse/refractory AML with FLT3 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zavorka Thomas, Megan E., Lu, Xiyuan, Talebi, Zahra, Jeon, Jae Yoon, Buelow, Daelynn R., Gibson, Alice A., Uddin, Muhammad Erfan, Brinton, Lindsey T., Nguyen, Julie, Collins, Meghan, Lodi, Alessia, Sweeney, Shannon R., Campbell, Moray J., Sweet, Douglas H., Sparreboom, Alex, Lapalombella, Rosa, Tiziani, Stefano, Baker, Sharyn D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687141/
https://www.ncbi.nlm.nih.gov/pubmed/34518298
http://dx.doi.org/10.1158/1535-7163.MCT-21-0071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687141/
https://www.ncbi.nlm.nih.gov/pubmed/34518298
http://dx.doi.org/10.1158/1535-7163.MCT-21-0071

Ejemplares similares